Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MALT1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MALT1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MALT1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MALT1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MALT1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MALT1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00508543 | Oral cavity | EOLP | regulation of antigen receptor-mediated signaling pathway | 15/2218 | 63/18723 | 5.86e-03 | 2.96e-02 | 15 |
GO:005109221 | Oral cavity | EOLP | positive regulation of NF-kappaB transcription factor activity | 29/2218 | 152/18723 | 6.29e-03 | 3.13e-02 | 29 |
GO:007121914 | Oral cavity | EOLP | cellular response to molecule of bacterial origin | 39/2218 | 221/18723 | 6.97e-03 | 3.39e-02 | 39 |
GO:00024604 | Oral cavity | EOLP | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 58/2218 | 356/18723 | 7.27e-03 | 3.52e-02 | 58 |
GO:00027203 | Oral cavity | EOLP | positive regulation of cytokine production involved in immune response | 15/2218 | 65/18723 | 7.93e-03 | 3.76e-02 | 15 |
GO:00024566 | Oral cavity | EOLP | T cell mediated immunity | 22/2218 | 109/18723 | 8.31e-03 | 3.91e-02 | 22 |
GO:00027021 | Oral cavity | EOLP | positive regulation of production of molecular mediator of immune response | 23/2218 | 117/18723 | 9.76e-03 | 4.42e-02 | 23 |
GO:00433721 | Oral cavity | EOLP | positive regulation of CD4-positive, alpha-beta T cell differentiation | 9/2218 | 32/18723 | 9.98e-03 | 4.51e-02 | 9 |
GO:00027031 | Oral cavity | EOLP | regulation of leukocyte mediated immunity | 39/2218 | 226/18723 | 1.01e-02 | 4.53e-02 | 39 |
GO:190332033 | Oral cavity | NEOLP | regulation of protein modification by small protein conjugation or removal | 72/2005 | 242/18723 | 2.44e-16 | 1.61e-13 | 72 |
GO:003139633 | Oral cavity | NEOLP | regulation of protein ubiquitination | 62/2005 | 210/18723 | 4.31e-14 | 1.60e-11 | 62 |
GO:000691331 | Oral cavity | NEOLP | nucleocytoplasmic transport | 75/2005 | 301/18723 | 1.56e-12 | 3.20e-10 | 75 |
GO:005116931 | Oral cavity | NEOLP | nuclear transport | 75/2005 | 301/18723 | 1.56e-12 | 3.20e-10 | 75 |
GO:005254733 | Oral cavity | NEOLP | regulation of peptidase activity | 98/2005 | 461/18723 | 1.77e-11 | 2.56e-09 | 98 |
GO:004586233 | Oral cavity | NEOLP | positive regulation of proteolysis | 80/2005 | 372/18723 | 7.28e-10 | 5.54e-08 | 80 |
GO:005254833 | Oral cavity | NEOLP | regulation of endopeptidase activity | 88/2005 | 432/18723 | 1.82e-09 | 1.18e-07 | 88 |
GO:004578532 | Oral cavity | NEOLP | positive regulation of cell adhesion | 88/2005 | 437/18723 | 3.28e-09 | 1.95e-07 | 88 |
GO:004312231 | Oral cavity | NEOLP | regulation of I-kappaB kinase/NF-kappaB signaling | 58/2005 | 249/18723 | 7.81e-09 | 4.09e-07 | 58 |
GO:200011632 | Oral cavity | NEOLP | regulation of cysteine-type endopeptidase activity | 55/2005 | 235/18723 | 1.59e-08 | 7.25e-07 | 55 |
GO:000724931 | Oral cavity | NEOLP | I-kappaB kinase/NF-kappaB signaling | 62/2005 | 281/18723 | 2.16e-08 | 9.59e-07 | 62 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa046607 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0515212 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa0466013 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
hsa0513114 | Liver | NAFLD | Shigellosis | 48/1043 | 247/8465 | 7.82e-04 | 1.17e-02 | 9.39e-03 | 48 |
hsa0513115 | Liver | NAFLD | Shigellosis | 48/1043 | 247/8465 | 7.82e-04 | 1.17e-02 | 9.39e-03 | 48 |
hsa0513142 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
hsa0513152 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
hsa0513116 | Lung | IAC | Shigellosis | 58/1053 | 247/8465 | 8.21e-07 | 3.81e-05 | 2.53e-05 | 58 |
hsa04625 | Lung | IAC | C-type lectin receptor signaling pathway | 26/1053 | 104/8465 | 3.15e-04 | 3.11e-03 | 2.06e-03 | 26 |
hsa04660 | Lung | IAC | T cell receptor signaling pathway | 23/1053 | 104/8465 | 3.88e-03 | 1.88e-02 | 1.25e-02 | 23 |
hsa0513117 | Lung | IAC | Shigellosis | 58/1053 | 247/8465 | 8.21e-07 | 3.81e-05 | 2.53e-05 | 58 |
hsa046251 | Lung | IAC | C-type lectin receptor signaling pathway | 26/1053 | 104/8465 | 3.15e-04 | 3.11e-03 | 2.06e-03 | 26 |
hsa046601 | Lung | IAC | T cell receptor signaling pathway | 23/1053 | 104/8465 | 3.88e-03 | 1.88e-02 | 1.25e-02 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MALT1 | SNV | Missense_Mutation | novel | c.1924G>A | p.Asp642Asn | p.D642N | Q9UDY8 | protein_coding | deleterious(0.02) | probably_damaging(0.911) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MALT1 | SNV | Missense_Mutation | novel | c.894N>A | p.Ser298Arg | p.S298R | Q9UDY8 | protein_coding | tolerated(0.54) | benign(0.015) | TCGA-A7-A3IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MALT1 | SNV | Missense_Mutation | | c.1364G>C | p.Gly455Ala | p.G455A | Q9UDY8 | protein_coding | tolerated(0.12) | probably_damaging(0.989) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MALT1 | SNV | Missense_Mutation | novel | c.1913N>G | p.Asp638Gly | p.D638G | Q9UDY8 | protein_coding | tolerated(0.1) | benign(0.145) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MALT1 | insertion | Frame_Shift_Ins | novel | c.2285_2286insCAGAATTGAGAATTCCTATTATAACCATAGATTGTTGTTTTCATTG | p.Ser763ArgfsTer20 | p.S763Rfs*20 | Q9UDY8 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
MALT1 | insertion | In_Frame_Ins | novel | c.2471_2472insTACTTGGTATCAAAGGATCTTCCCAAGCATTGCCTCTAT | p.Lys824delinsAsnThrTrpTyrGlnArgIlePheProSerIleAlaSerIle | p.K824delinsNTWYQRIFPSIASI | Q9UDY8 | protein_coding | | | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MALT1 | insertion | Nonsense_Mutation | novel | c.1324_1325insGAAGTTCAGACTGA | p.Val442GlyfsTer5 | p.V442Gfs*5 | Q9UDY8 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MALT1 | insertion | Frame_Shift_Ins | novel | c.1326_1327insTTTTTGTTGTTTTTTACAGC | p.Gln443PhefsTer11 | p.Q443Ffs*11 | Q9UDY8 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MALT1 | SNV | Missense_Mutation | rs780898848 | c.1175N>A | p.Arg392His | p.R392H | Q9UDY8 | protein_coding | tolerated(0.17) | benign(0.031) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MALT1 | SNV | Missense_Mutation | | c.1423C>G | p.Pro475Ala | p.P475A | Q9UDY8 | protein_coding | tolerated(0.23) | benign(0.217) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |